Deutsche Bank Ag\ Genmab A/S Transaction History

Deutsche Bank Ag\

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$27.94 - $35.44 $158,503 - $201,051	5,673 New	5,673 $180,000
Q2 2023 Aug 14, 2023	BUY	$37.4 - $42.94 $72,967 - $83,775	1,951 New	1,951 $74,000
Q4 2021 Feb 11, 2022	SELL	$35.87 - $47.12 $1,542 - $2,026	-43 Closed	0 $0
Q3 2021 Nov 04, 2021	SELL	$41.55 - $48.72 $285,614 - $334,901	-6,874 Reduced 99.38%	43 $2,000
Q2 2021 Aug 11, 2021	SELL	$32.88 - $44.57 $7,661 - $10,384	-233 Reduced 3.26%	6,917 $282,000
Q1 2021 May 13, 2021	SELL	$30.92 - $44.4 $32,775 - $47,064	-1,060 Reduced 12.91%	7,150 $234,000
Q4 2020 Feb 16, 2021	BUY	$33.66 - $40.76 $276,348 - $334,639	8,210 New	8,210 $334,000
Q3 2020 Nov 12, 2020	SELL	$33.07 - $38.68 $593,441 - $694,112	-17,945 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$20.05 - $33.89 $359,797 - $608,156	17,945 New	17,945 $608,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

Stay updated on Deutsche Bank Ag\ with notifications on news.